Table 2 Treatment-related (A: atezolizumab and B: SBRT) Adverse Events in Study Population per CTCAE

A

Grade

SOC

Preferred term

1

2

3

Blood and lymphatic system disorders

Lymphopenia

1 (2%)

Gastrointestinal disorders

Dysphagia

1 (2%)

General disorders and administration site conditions

Chills

1 (2%)

Hepatobiliary disorders

Hepatic Cytolysis

1 (2%)

Immune system disorders

Autoimmune Hepatitis

1 (2%)

Investigations

CPK increased

1 (2%)

Weight loss

1 (2%)

Metabolism and nutrition disorders

Anorexia

1 (2%)

Musculoskeletal and connective tissue disorders

Myalgia

1 (2%)

Myositis

1 (2%)

Respiratory, thoracic and mediastinal disorders

Dyspnea

1 (2%)

Pneumonitis

1 (2%)

Skin and subcutaneous tissue disorders

Folliculitis

1 (2%)

Psoriasis

1 (2%)

B

Grade

SOC

Preferred term

1

2

Infections and infestations

Urinary tract infection

1 (2%)

Neoplasms benign, malignant and unspecified

Tumor pain

1 (2%)

1 (2%)